Gyre Therapeutics (GYRE) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Gyre Therapeutics (GYRE) has outperformed Wave Life Sciences (WVE) over the past year, losing 7.4% versus a loss of 52.8%. Over five years, WVE leads with a -32.6% price change compared with -88.7% for GYRE. Gyre Therapeutics is the larger company by market cap ($744.4 million vs $689.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GYRE | WVE |
|---|---|---|
| Share price | $7.02 | $3.50 |
| Market cap | $744.36M | $689.67M |
| 1-day change | +3.85% | +0.87% |
| YTD return | -4.25% | -79.59% |
| 1-year return | -7.40% | -52.79% |
| 5-year return | -88.73% | -32.62% |
| Forward P/E | 117.00 | — |
| EPS (TTM) | $-0.25 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.42 | $21.73 |
| 52-week low | $5.44 | $3.37 |
| Distance from 52-week high | -25.48% | -83.89% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +165.95% | +416.00% |
| Average volume | 105.93K | 3.12M |
| Shares outstanding | 106.03M | 197.05M |
| Employees | 625 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GYRE has outperformed WVE by 45.4 percentage points over the past year.
About Gyre Therapeutics
GYRE stock →Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 625 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
GYRE vs WVE FAQ
Which is bigger, Gyre Therapeutics or Wave Life Sciences?
Gyre Therapeutics (GYRE) is larger, with a market capitalization of $744.36M compared with $689.67M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, GYRE or WVE?
GYRE returned -7.40% over the past 12 months, compared with -52.79% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Gyre Therapeutics and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.